Eosinophil-Derived Neurotoxin Is Elevated in Patients with Amyotrophic Lateral Sclerosis
Table 2
The concentrations of EDN and ECP in sera from patients with ALS, AD, and PD and from controls.
Group ()
EDNa
ECPa
mean (SD, range)
mean (range)
P value
P value
Control
AD
PD
ALS
Control
AD
PD
ALS
Control (44)
21.0 (14.9, 8.6–79.4)
—
21.1 (27.4, 1.7–109.9)
—
AD (39)
28.3 (36.6, 1.9–158.0)
0.23
—
15.4 (17.4, 0–97.1)
0.26
—
PD (40)
24.8 (20.7, 3.1–95.5)
0.33
0.61
—
15.8 (15.2, 0–77.8)
0.27
0.73
—
ALS (44)
45.7 (29.3, 8.9–140.9)
<0.005
0.01
0.02
—
24.1 (24.5, 0.4–88.8)
0.06
0.07
0.06
—
bALSFRS-R
P value
P value
Control
0–9
10–19
20–29
30–39
40–47
Control
0–9
10–19
20–29
30–39
40–47
0–9 (15)
42.6 (27.6, 11.9–99.9)
0.63
—
18.7 (19.1, 4.3–77.7)
0.60
—
10–19 (11)
45.9 (37.5, 8.9–140.9)
0.17
0.24
—
25.6 (27.4, 4.3–78.4)
0.43
0.71
—
20–29 (7)
39.9 (21.1, 14.6–69.7)
0.08
0.59
0.90
—
21.6 (22.5, 6.3–66.3)
0.20
0.50
0.91
—
30–39 (7)
51.3 (25.8, 17.9–89.3)
0.27
0.35
0.66
0.49
—
26.2 (27.6, 0.4–77.5)
0.35
0.66
0.17
0.96
—
40–47 (4)
57.4 (37.6, 18.3–108.7)
0.75
0.75
0.33
0.33
0.92
—
40.9 (35.4, 12.1–88.8)
0.42
0.75
0.33
0.33
0.42
—
cDuration
P value
P value
Control
1–12
13–24
25–36
>37
Control
1–12
13–24
25–36
>37
1–12 (31)
50.3 (32.7, 8.9–140.9)
0.83
—
18.9 (20.3, 4.3–77.4)
0.75
—
13–24 (8)
31.3 (12.2, 16.6–48.6)
0.13
0.27
—
32.5 (31.2, 4.3–88.8)
0.88
0.70
—
25–36 (3)
49.0 (15.1, 33.2–50.2)
NA
fNA
NA
—
58.5 (24.1, 31.5–77.7)
NA
NA
0.33
—
>37 (2)
27.9 (13.2, 18.6–37.3)
NA
NA
NA
NA
—
18.4 (17.1, 6.3–30.5)
NA
NA
NA
NA
—
dAge
P value
P value
Control
41–50
51–60
61–70
71–80
Control
41–50
51–60
61–70
71–80
41–50 (7)
58.9 (42.2, 20.9–140.9)
0.30
—
40.7 (30.6, 10.9–78.4)
0.56
—
51–60 (19)
35.8 (21.2, 8.9–101.8)
0.06
0.49
—
19.3 (21.1, 4.3–77.7)
0.82
0.56
—
61–70 (13)
53.5 (30.2, 14.6–108.7)
0.48
0.44
0.91
—
65.4 (26.3, 6.4–88.8)
0.72
0.57
0.93
—
71–80 (5)
45 (28.1, 16.6–83.4)
0.45
0.95
0.45
0.35
—
9.9 (7.8, 0.4–20)
0.78
0.45
0.68
0.35
—
eOnset type
P value
P value
Control
Brainstem
Hand
Foot
Control
Brainstem
Hand
Foot
Brainstem (13)
42.4 (25.2, 14.6–99.9)
0.89
—
19.8 (21.9, 4.3–77.7)
0.54
—
Hand (12)
51.1 (30.9, 8.9–108.7)
0.68
0.54
—
22.9 (28.7, 6.2–77.5)
0.90
0.86
—
Foot (19)
44.7 (32.3, 11.9–140.9)
0.92
0.88
0.62
—
27.7 (20.4, 0.42–88.8)
0.39
0.46
0.39
—
aConcentrations are expressed as ng/mL.
bALSFRS-R is a score from 0 to 48 which assesses disability in patients with motor neuron diseases. 0 means serious, and 48 means normal.
cCategories are based on the duration of symptoms (months).
dCategories indicate age at time of blood collection (years).
eCategories indicate the type of onset.
fThe NA were divided according to the unanalyzable group (sample number of subgroup <3). The one-way ANOVA test and Bonferroni multiple comparison test were used to determine the significance among the test groups of control, AD, PD, and ALS. The Spearman rank correlation test was used to correlate the levels of EDN and ECP versus the subgroups of age, ALSFRS-R, duration, and onset types.
